Cogent Biosciences, Inc. (COGT)

Market Cap	712.25M
Revenue (ttm)	n/a
Net Income (ttm)	-177.66M
Shares Out	86.12M
EPS (ttm)	-2.33
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	18,070
Open	8.19
Previous Close	8.27
Day's Range	8.13 - 8.27
52-Week Range	6.43 - 15.68
Beta	-0.20
Analysts	Strong Buy
Price Target	22.83 (+178.08%)
Earnings Date	Nov 2, 2023

About COGT

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target exon 17 mutations found within the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercializat...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 29, 2018
• Employees: 138
• Stock Exchange: NASDAQ
• Ticker Symbol: COGT

Analyst Forecast

According to 6 analysts, the average rating for COGT stock is "Strong Buy." The 12-month stock price forecast is $22.83, which is an increase of 178.08% from the latest price.

Price Target

$22.83

(178.08% upside)

Analyst Consensus: Strong Buy